Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

BioCryst Pharmaceuticals and Idera Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference

2018-03-22 globenewswire
RESEARCH TRIANGLE PARK, N.C. and EXTON, Pa., March 22, 2018 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (“BioCryst”) (NASDAQ:BCRX), and Idera Pharmaceuticals, Inc. (“Idera”) (NASDAQ:IDRA), today announced they will be presenting at the 17th Annual Needham Healthcare Conference on Tuesday, March 27, 2018 at 12:15 P.M. E.T. The conference is being held at the Westin New York Grand Central Hotel. (97-0)

Biotech Analysis Central Pharma News: Biogen Pulls MS Drug, Roche's And Ionis' Huntington's Drug Advance, Idera's Hope

2018-03-05 seekingalpha
Biogen and Abbvie pull their multiple sclerosis drug Zinbryta off the market due to safety concerns. (195-1)

Your Daily Pharma Scoop: Portola Drops On AndexXa Update, NovaVax Top-Line Results, Idera Commences Late-Stage Study With IMO-2125

2018-03-02 seekingalpha
Portola Pharmaceuticals (PTLA) shares have opened more than 25% lower amid speculation that the company’s AndexXa will require an additional trial before the FDA approves the BLA. (575-1)

BioCryst Pharmaceuticals, Inc. (BCRX) CEO Jon Stonehouse Q4 2017 Results - Earnings Call Transcript

2018-02-28 seekingalpha
Good day, ladies and gentlemen. And welcome to the BioCryst Pharmaceuticals Incorporated Fourth Quarter 2017 Earnings Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct the question-and-answer session and instructions will be given at that time [Operator Instructions]. As a reminder, this call is being recorded. (97-0)

BioXcel Therapeutics Seeks $69 Million U.S. IPO

2018-02-16 seekingalpha
The firm is using the advanced data and AI technologies of its parent company to improve its drug development efforts. (381-5)

BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall

2018-01-23 zacks
BioCryst Pharmaceuticals, Inc. (BCRX - Free Report) and Idera Pharmaceuticals, Inc. (IDRA - Free Report) announced that they have entered into a definitive merger agreement. The merged entity will focus on development and commercialization of drugs to treat rare diseases. (128-5)

BRIEF-Biocryst Pharma And Idera Pharma Sign Merger Agreement To Form New Company

2018-01-22 reuters

BioCryst and Idera to merge into rare disease company - MarketWatch

2018-01-22 marketwatch
BioCryst Pharmaceuticals Inc. BCRX, -1.58% and Idera Pharmaceuticals Inc. IDRA, +6.03% announced early Monday plans to merge into a rare disease company. Shares of both companies were halted in premarket trade. Under the deal, which is expected to be completed by the second quarter of 2018, shares of BioCryst will be exchanged for 0.5 shares of the new company's stock and Idera shares will be exchanged for 0. (97-2)

Stocks To Watch: Earnings Season Hits Higher Gear

2018-01-20 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (828-10)

7 High-Risk, High-Reward Stocks to Buy Now | InvestorPlace

2018-01-11 investorplace
U.S. equities have rebounded from a short-lived scare regarding a possible pullback of Chinese buying of U.S. Treasury bonds. The holiday-season melt has resumed, with stocks enjoying one of their strongest starts to a year on record. Just days after the Dow Jones Industrial Average passed the 25,000 threshold for the first time, the index is now closer to 26,000 than that level. (167-3)

Your Daily Pharma Scoop: Lipocine Ahead Of Ad Com, Ohr's MAKO Study Fails, Zafgen Provides Update

2018-01-06 seekingalpha
Today we will discuss Lipocine (LPCN), which fell more than 10% on Friday ahead of the Ad Com for its lead product candidate TLANDO, an oral testosterone replacement therapy (TRT). (243-7)

Pieris Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors

2017-11-21 marketwired
BOSTON, MA--(Marketwired - November 21, 2017) - Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that James Geraghty has been appointed Chairman of the Board of Directors. Mr. Geraghty replaces Chau Q. Khuong, who is stepping down from the Board after helping guide Pieris through platform validation and partnerships to its transition into a fully-integrated research and clinical development company. (118-1)

Is the Options Market Predicting a Spike in Idera (IDRA) Stock?

2017-11-10 zacks
Investors in Idera Pharmaceuticals, Inc. (IDRA - Free Report) need to pay close attention to the stock based on moves in the options market lately. That is because the Nov 17, 2017 $4 Put had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. (73-2)

IDRA / Idera Pharmaceuticals, Inc. - Stock Institutional Ownership and Shareholders -

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has 80 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 54,821,190 shares. Largest shareholders include Baker Brothers Advisors LP, BlackRock Inc., Vanguard Group Inc, Broadfin Capital, LLC, and FMR LLC / Fidelity Management & Research. (104-2)

Stock Performance Review on Biotech Industry -- Galena Biopharma, Idera Pharma, Ignyta, and Jaguar Health

2017-09-18 prnewswire
If you want a Stock Review on GALE, IDRA, RXDX, or JAGX then come over to and sign up for your free customized report today. On Friday, the NASDAQ Composite ended the day at 6,448.47, up 0.30%; the Dow Jones Industrial Average edged 0.29% higher, to finish at 22,268.34; and the S&P 500 closed at 2,500.23, marginally gaining 0.18%. Gains were broad based as six out of nine sectors finished the trading session in green. (207-4)